TGM2 and renal cell carcinoma: Elevated TG2 expression has been demonstrated in a number of cancers such as pancreatic [30], breast [31], melanoma [32], ovary [33], lung [34], and lastly RCC [35,36], in association with cancer progression, drug resistance, metastatic spread, and poor patient survival.